|
US1910220A
(en)
*
|
1931-10-21 |
1933-05-23 |
Kremser Alois |
Mechanically operated gate
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
CA2103059C
(en)
|
1991-06-14 |
2005-03-22 |
Paul J. Carter |
Method for making humanized antibodies
|
|
US5994618A
(en)
|
1997-02-05 |
1999-11-30 |
Johns Hopkins University School Of Medicine |
Growth differentiation factor-8 transgenic mice
|
|
WO1994021681A1
(en)
|
1993-03-19 |
1994-09-29 |
Johns Hopkins University School Of Medicine |
Growth differentiation factor-8
|
|
EP1075272B1
(en)
|
1998-05-06 |
2009-07-15 |
Metamorphix, Inc. |
Methods for treating diabetes by inhibiting gdf-8
|
|
US6927044B2
(en)
|
1998-09-25 |
2005-08-09 |
Regeneron Pharmaceuticals, Inc. |
IL-1 receptor based cytokine traps
|
|
WO2001005820A2
(en)
|
1999-07-20 |
2001-01-25 |
Pharmexa A/S |
Method for down-regulating gdf-8 activity
|
|
US6670140B2
(en)
|
2001-03-06 |
2003-12-30 |
The Procter & Gamble Company |
Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
|
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
|
US7241444B2
(en)
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
|
AR047392A1
(es)
|
2002-10-22 |
2006-01-18 |
Wyeth Corp |
Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
|
|
US20040101920A1
(en)
|
2002-11-01 |
2004-05-27 |
Czeslaw Radziejewski |
Modification assisted profiling (MAP) methodology
|
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
|
US7785587B2
(en)
|
2003-06-02 |
2010-08-31 |
Wyeth |
Therapeutic methods for muscular or neuromuscular disorders
|
|
BRPI0418317A
(pt)
|
2003-12-31 |
2007-05-02 |
Schering Plough Ltd |
vacina de aumento de crescimento à base de epitopo de neutralização
|
|
EP3006039B1
(en)
|
2004-03-02 |
2021-01-06 |
Acceleron Pharma Inc. |
Alk7 polypeptides for use in promoting fat loss
|
|
CA2558805C
(en)
|
2004-03-23 |
2011-09-27 |
Eli Lilly And Company |
Anti-myostatin antibodies
|
|
WO2005103081A2
(en)
|
2004-04-20 |
2005-11-03 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
|
AU2005272646A1
(en)
|
2004-08-12 |
2006-02-23 |
Wyeth |
Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors
|
|
NZ538097A
(en)
|
2005-02-07 |
2006-07-28 |
Ovita Ltd |
Method and compositions for improving wound healing
|
|
EP1877075A4
(en)
|
2005-04-25 |
2008-07-30 |
Pfizer |
ANTIBODY TO MYOSTATIN
|
|
WO2006122079A1
(en)
|
2005-05-06 |
2006-11-16 |
Zymogenetics, Inc. |
Il-31 monoclonal antibodies and methods of use
|
|
EP1773041A1
(en)
|
2005-07-21 |
2007-04-11 |
Chao-Hung Wu |
Audio/video data transmission system using the internet to interconnect telephones
|
|
EP2407486B1
(en)
|
2005-08-19 |
2017-11-22 |
Wyeth LLC |
Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders
|
|
EA015589B1
(ru)
|
2005-10-06 |
2011-10-31 |
Эли Лилли Энд Компани |
Антитела против миостатина и их применение
|
|
UA92504C2
(en)
*
|
2005-10-12 |
2010-11-10 |
Эли Лилли Энд Компани |
Anti-myostatin monoclonal antibody
|
|
US8128933B2
(en)
|
2005-11-23 |
2012-03-06 |
Acceleron Pharma, Inc. |
Method of promoting bone growth by an anti-activin B antibody
|
|
AU2006321906C1
(en)
|
2005-12-06 |
2014-01-16 |
Amgen Inc. |
Uses of myostatin antagonists
|
|
WO2007143168A2
(en)
|
2006-06-02 |
2007-12-13 |
Regeneron Pharmaceuticals, Inc. |
High affinity antibodies to human il-6 receptor
|
|
CA2693378C
(en)
|
2006-08-03 |
2020-04-14 |
Orico Limited |
Myostatin antagonists
|
|
KR101123531B1
(ko)
|
2006-09-05 |
2012-04-20 |
일라이 릴리 앤드 캄파니 |
항-마이오스타틴 항체
|
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
|
US7947646B2
(en)
|
2007-03-06 |
2011-05-24 |
Amgen Inc. |
Variant activin receptor polypeptides
|
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
|
PT2463282E
(pt)
|
2007-11-05 |
2013-11-11 |
Novartis Ag |
Derivados de 4-benzilamino-1-carboxiacil-piperidina como inibidores de cetp úteis para o tratamento de doenças tais como hiperlipidemia ou arteriosclerose
|
|
TWI748373B
(zh)
|
2008-08-14 |
2021-12-01 |
美商艾瑟勒朗法瑪公司 |
使用gdf阱以增加紅血球水平
|
|
TW201029662A
(en)
|
2008-12-19 |
2010-08-16 |
Glaxo Group Ltd |
Novel antigen binding proteins
|
|
WO2010083034A1
(en)
|
2009-01-13 |
2010-07-22 |
Acceleron Pharma Inc. |
Methods for increasing adiponectin
|
|
EP2424895B1
(en)
|
2009-04-27 |
2017-09-06 |
Novartis AG |
Compositions and methods for increasing muscle growth
|
|
MY199658A
(en)
|
2009-06-26 |
2023-11-14 |
Regeneron Pharma |
Readily isolated bispecific antibodies with native immunoglobulin format
|
|
US8710016B2
(en)
|
2009-11-17 |
2014-04-29 |
Acceleron Pharma, Inc. |
ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
|
|
JO3340B1
(ar)
*
|
2010-05-26 |
2019-03-13 |
Regeneron Pharma |
مضادات حيوية لـعامل تمايز النمو 8 البشري
|
|
AR081556A1
(es)
|
2010-06-03 |
2012-10-03 |
Glaxo Group Ltd |
Proteinas de union al antigeno humanizadas
|
|
JP2013537425A
(ja)
|
2010-08-16 |
2013-10-03 |
アムジエン・インコーポレーテツド |
ミオスタチンに結合するポリペプチド、組成物および方法
|
|
CN103298832A
(zh)
|
2010-11-08 |
2013-09-11 |
阿塞勒隆制药公司 |
Actriia结合剂及其用途
|
|
RU2674036C2
(ru)
|
2011-05-16 |
2018-12-04 |
Джензим Корпорейшн |
Индукция иммунологической толерантности, используя метотрексат
|
|
HUE038570T2
(hu)
|
2011-11-14 |
2018-10-29 |
Regeneron Pharma |
Készítmények és eljárások izomtömeg és izomerõ növelésére GDF8 és/vagy aktivin A specifikus antagonizálásával
|
|
GR1007832B
(el)
|
2011-11-21 |
2013-02-14 |
Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, |
Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
|
|
WO2013186719A1
(en)
*
|
2012-06-15 |
2013-12-19 |
Pfizer Inc. |
Improved antagonist antibodies against gdf-8 and uses therefor
|
|
US20150203591A1
(en)
|
2012-08-02 |
2015-07-23 |
Regeneron Pharmaceuticals, Inc. |
Mutivalent antigen-binding proteins
|
|
AU2014212014A1
(en)
|
2013-02-01 |
2015-08-27 |
Amgen Inc. |
Administration of an anti-activin-A compound to a subject
|
|
TWI655207B
(zh)
|
2013-07-30 |
2019-04-01 |
再生元醫藥公司 |
抗活化素ａ之抗體及其用途
|
|
BR112016002198A2
(pt)
*
|
2013-08-14 |
2017-09-12 |
Novartis Ag |
métodos de tratamento de miosite por corpos de inclusão esporádica
|
|
US20160075772A1
(en)
|
2014-09-12 |
2016-03-17 |
Regeneron Pharmaceuticals, Inc. |
Treatment of Fibrodysplasia Ossificans Progressiva
|
|
CN107771081A
(zh)
|
2015-04-15 |
2018-03-06 |
瑞泽恩制药公司 |
用gdf8抑制剂增加力量和功能的方法
|
|
US20180008672A1
(en)
|
2016-07-08 |
2018-01-11 |
Regeneron Pharmaceuticals, Inc. |
Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
|
|
CA3092334A1
(en)
|
2018-03-01 |
2019-09-06 |
Regeneron Pharmaceuticals, Inc. |
Methods for altering body composition
|